[5] Saxena AR, Frias JP, Brown LS, et al. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(5):e2314493. Published 2023 May 1. do...
There are several other types ofdiabetes medications, like oral (taken by mouth) medications. One type oforalmedication,metformin, is the go-to medication for treating T2D. But your healthcare provider may recommend a GLP-1 agonist if: oral :口服的 metformin:二甲双胍 go-to:首选 Metformin isn...
4. LINJAWI S, BODE B W, CHAYKIN L B, et al. The Efficacy of IdegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomi...
[15] Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. [16] Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orfo...
[4] A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor, J Med Chem, 2022 [5] https://www.lilly.com/news/media/media-kits/mounjaro [6] https://clinicaltrials.gov/ct2/show/NCT05869903?term=Orforglipron&draw=2&rank=2 ...
2023年6月23日,礼来公司(Eli Lilly)的研究人员在《新英格兰医学杂志》(NEJM)发表了题为:Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity的临床研究论文。 在这项2期临床试验中,礼来开发的口服减肥药物Orforglipron,在最高剂量用药36周后,帮助肥胖者平均减重14.7%,这一效果可与诺和诺德...
Acute Gallbladder Disease:Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1% of patients treated with RYBELSUS®7 mg. Cholelithiasis was not ...
in PhII data. Retrieved May 23, 2023, from https://endpts.com/pfizers-oral-glp-1-shows-weight-loss-potential-in-new-phii-data/.4.http://cn.innoventbio.com/#/news/485.5.https://www.boehringer-ingelheim.com/bi-456909-glp1/gcgr-agonist-0.文章来源：【药渡Daily】公众号/微茫原创 ...
3.Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial.Notified. 4.The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-...
[1] Aditi R. Saxena et al. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes:A Randomized Clinical Trial. JAMA Network O...